RU2013118454A - Антитело к эфрину в2 и его применение - Google Patents
Антитело к эфрину в2 и его применение Download PDFInfo
- Publication number
- RU2013118454A RU2013118454A RU2013118454/10A RU2013118454A RU2013118454A RU 2013118454 A RU2013118454 A RU 2013118454A RU 2013118454/10 A RU2013118454/10 A RU 2013118454/10A RU 2013118454 A RU2013118454 A RU 2013118454A RU 2013118454 A RU2013118454 A RU 2013118454A
- Authority
- RU
- Russia
- Prior art keywords
- polypeptide
- antibody
- polypeptide according
- efrin
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP201031402 | 2010-09-21 | ||
| ES201031402A ES2378976B1 (es) | 2010-09-21 | 2010-09-21 | Anticuerpo contra ephrin b2 y su uso. |
| PCT/ES2011/070655 WO2012038573A1 (es) | 2010-09-21 | 2011-09-20 | Anticuerpo contra ephrin b2 y su uso |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013118454A true RU2013118454A (ru) | 2014-10-27 |
Family
ID=45873482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013118454/10A RU2013118454A (ru) | 2010-09-21 | 2011-09-20 | Антитело к эфрину в2 и его применение |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9062109B2 (enExample) |
| EP (1) | EP2620449A4 (enExample) |
| JP (1) | JP2013542720A (enExample) |
| KR (1) | KR20140014062A (enExample) |
| CN (1) | CN103237812A (enExample) |
| AU (1) | AU2011306816A1 (enExample) |
| BR (1) | BR112013005977A2 (enExample) |
| CA (1) | CA2812727A1 (enExample) |
| ES (1) | ES2378976B1 (enExample) |
| MX (1) | MX2013003168A (enExample) |
| RU (1) | RU2013118454A (enExample) |
| WO (1) | WO2012038573A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104694477B (zh) * | 2015-03-03 | 2018-04-17 | 西安交通大学 | 一种EphrinB2高表达的重组HEK293细胞及其应用 |
| JP2022516611A (ja) * | 2018-12-28 | 2022-03-01 | ザ ジェネラル ホスピタル コーポレイション | 線維性疾患の治療のための抗エフリン－ｂ２遮断抗体 |
| US20220213214A1 (en) * | 2019-05-14 | 2022-07-07 | Sanford Health | Anti-human ephrin B1 antibodies and uses thereof |
| WO2020242910A1 (en) * | 2019-05-24 | 2020-12-03 | The Regents Of The University Ofcalifornia | Compositions and methods for treating cancer |
| TW202547871A (zh) * | 2024-03-27 | 2025-12-16 | 美商麥第爾醫療公司 | 抗ｅｐｈｒｉｎ ｂ２抗體及使用方法 |
| CN121159668A (zh) * | 2025-09-12 | 2025-12-19 | 北京威斯克生物医药有限公司 | Ephrin-B2重组蛋白及其疫苗、制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004260884B2 (en) * | 2003-07-22 | 2009-11-19 | Crucell Holland B.V. | Binding molecules against SARS-coronavirus and uses thereof |
| JP2007320850A (ja) * | 2004-08-24 | 2007-12-13 | Kyowa Hakko Kogyo Co Ltd | 抗エフリンｂ２抗体 |
| EP1954720A1 (en) * | 2005-10-31 | 2008-08-13 | The Government of the United States of America, as represented by the Secretary of Health and Human Services, National Institutes of Health | Antibodies and immunotoxins that target human glycoprotein nmb |
| RU2451031C2 (ru) * | 2006-01-20 | 2012-05-20 | Дженентек, Инк. | Антитела к эфрину в2 и способы их применения |
| PL1972637T3 (pl) * | 2007-03-19 | 2012-01-31 | Univ Stuttgart | Antagoniści selektywni wobec huTNFR1 |
| WO2010019565A2 (en) * | 2008-08-12 | 2010-02-18 | Medlmmune, Llc | Anti-ephrin b2 antibodies and their use in treatment of disease |
-
2010
- 2010-09-21 ES ES201031402A patent/ES2378976B1/es not_active Expired - Fee Related
-
2011
- 2011-09-20 KR KR1020137007045A patent/KR20140014062A/ko not_active Withdrawn
- 2011-09-20 US US13/824,171 patent/US9062109B2/en not_active Expired - Fee Related
- 2011-09-20 CN CN2011800534643A patent/CN103237812A/zh active Pending
- 2011-09-20 MX MX2013003168A patent/MX2013003168A/es not_active Application Discontinuation
- 2011-09-20 RU RU2013118454/10A patent/RU2013118454A/ru not_active Application Discontinuation
- 2011-09-20 JP JP2013528731A patent/JP2013542720A/ja active Pending
- 2011-09-20 CA CA2812727A patent/CA2812727A1/en not_active Abandoned
- 2011-09-20 EP EP11826446.4A patent/EP2620449A4/en not_active Withdrawn
- 2011-09-20 BR BR112013005977A patent/BR112013005977A2/pt not_active IP Right Cessation
- 2011-09-20 AU AU2011306816A patent/AU2011306816A1/en not_active Withdrawn
- 2011-09-20 WO PCT/ES2011/070655 patent/WO2012038573A1/es not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN103237812A (zh) | 2013-08-07 |
| WO2012038573A1 (es) | 2012-03-29 |
| CA2812727A1 (en) | 2012-03-29 |
| KR20140014062A (ko) | 2014-02-05 |
| MX2013003168A (es) | 2013-08-21 |
| US9062109B2 (en) | 2015-06-23 |
| US20130287795A1 (en) | 2013-10-31 |
| EP2620449A1 (en) | 2013-07-31 |
| ES2378976B1 (es) | 2013-05-06 |
| EP2620449A4 (en) | 2014-03-26 |
| JP2013542720A (ja) | 2013-11-28 |
| BR112013005977A2 (pt) | 2019-09-24 |
| AU2011306816A1 (en) | 2013-04-04 |
| ES2378976A1 (es) | 2012-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220214344A1 (en) | Method, array and use thereof | |
| Camporeale et al. | K8 and K12 are biotinylated in human histone H4 | |
| US10705089B2 (en) | Methods and kits for the diagnosis of cancer | |
| ES2315697T3 (es) | Deteccion de modificacion de historia en nucleosomas libres de celulas. | |
| Kolovskaya et al. | DNA-aptamer/protein interaction as a cause of apoptosis and arrest of proliferation in Ehrlich ascites adenocarcinoma cells | |
| Martinelli et al. | ZASP interacts with the mechanosensing protein Ankrd2 and p53 in the signalling network of striated muscle | |
| JP2013542720A5 (enExample) | ||
| Zhang et al. | Proteomics‐driven identification of short open reading frame‐encoded peptides | |
| JPWO2021075545A5 (enExample) | ||
| Bhattacharya et al. | Histone isoform H2A1H promotes attainment of distinct physiological states by altering chromatin dynamics | |
| RU2013104137A (ru) | Изоформы bard1 при раке легкого и колоректальном раке и их применение | |
| Gómez-Marín et al. | The high mobility group protein HMG20A cooperates with the histone reader PHF14 to modulate TGFβ and Hippo pathways | |
| AU2006246342A1 (en) | Melanoma-associated endogenous retrovirus (MERV) derived peptide sequences and their therapeutic/ diagnostic use | |
| KR102525734B1 (ko) | 데옥시하이푸신·신타제 유전자를 지표로서 사용하는 동맥 경화 및 암의 검출 방법 | |
| JP2017515107A (ja) | がんを検出するための方法およびバイオマーカー | |
| US20220281931A1 (en) | Chemically inducible polypeptide polymerization | |
| Mucha et al. | Auto-inhibition of PRC2 by the broadly expressed long isoform of AEBP2 | |
| RU2011104704A (ru) | Средство для индукции иммунитета и способ выявления злокачественной опухоли | |
| US10739344B2 (en) | Zinc finger linker (ZnFL) antibody | |
| Henderson et al. | A balance between actin and Eps8/IRSp53 utilization in branched versus linear actin networks determines tunneling nanotube formation | |
| Gruber-Olipitz et al. | Synthesis, chaperoning, and metabolism of proteins are regulated by NT-3/TrkC signaling in the medulloblastoma cell line DAOY | |
| Gömöryová et al. | Proximity interactomics identifies RAI14, EPHA2 and PHACTR4 as essential components of Wnt/planar cell polarity pathway in vertebrates | |
| KR20160050727A (ko) | 리포칼린 2 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도 | |
| CA3103147A1 (en) | Biomarkers for urothelial carcinoma and applications thereof | |
| Gomez-Marın et al. | The high mobility group protein HMG20A cooperates with the histone reader PHF14 to modulate TGFß and Hippo pathways |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20140922 |